🚀 VC round data is live in beta, check it out!
enGene Valuation Multiples
Discover revenue and EBITDA valuation multiples for enGene and similar public comparables like Alkaloid, Luzhu Biotech, uniQure, Lexicon Pharmaceuticals and more.
enGene Overview
About enGene
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Founded
2023
HQ
Employees
82
Website
Financials (LTM)
EV
$507M
enGene Financials
enGene reported last 12-month revenue of — and negative EBITDA of ($125M).
In the same LTM period, enGene generated — in gross profit, ($125M) in EBITDA losses, and had net loss of ($125M).
Revenue (LTM)
enGene P&L
In the most recent fiscal year, enGene reported revenue of — and EBITDA of ($114M).
enGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($125M) | XXX | ($114M) | XXX | XXX | XXX |
| Net Profit | ($125M) | XXX | ($117M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
enGene Stock Performance
enGene has current market cap of $669M, and enterprise value of $507M.
Market Cap Evolution
enGene's stock price is $9.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $507M | $669M | 0.0% | XXX | XXX | XXX | $-1.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialenGene Valuation Multiples
enGene trades at (4.1x) EV/EBITDA.
enGene Financial Valuation Multiples
As of March 21, 2026, enGene has market cap of $669M and EV of $507M.
Equity research analysts estimate enGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
enGene has a P/E ratio of (5.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $669M | XXX | $669M | XXX | XXX | XXX |
| EV (current) | $507M | XXX | $507M | XXX | XXX | XXX |
| EV/EBITDA | (4.1x) | XXX | (4.5x) | XXX | XXX | XXX |
| EV/EBIT | (3.9x) | XXX | (4.1x) | XXX | XXX | XXX |
| P/E | (5.3x) | XXX | (5.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified enGene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
enGene Margins & Growth Rates
enGene's revenue in the last fiscal year grew by —.
enGene's revenue per employee in the last FY averaged $0.0M.
enGene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 9% | XXX | 20% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
enGene Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alkaloid | XXX | XXX | XXX | XXX | XXX | XXX |
| Luzhu Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| uniQure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexicon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| TTY Biopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
enGene M&A Activity
enGene acquired XXX companies to date.
Last acquisition by enGene was on XXXXXXXX, XXXXX. enGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by enGene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialenGene Investment Activity
enGene invested in XXX companies to date.
enGene made its latest investment on XXXXXXXX, XXXXX. enGene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by enGene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout enGene
| When was enGene founded? | enGene was founded in 2023. |
| Where is enGene headquartered? | enGene is headquartered in Canada. |
| How many employees does enGene have? | As of today, enGene has over 82 employees. |
| Who is the CEO of enGene? | enGene's CEO is Ronald Harold Wilfred Cooper. |
| Is enGene publicly listed? | Yes, enGene is a public company listed on Nasdaq. |
| What is the stock symbol of enGene? | enGene trades under ENGN ticker. |
| When did enGene go public? | enGene went public in 2023. |
| Who are competitors of enGene? | enGene main competitors are Alkaloid, Luzhu Biotech, uniQure, Lexicon Pharmaceuticals. |
| What is the current market cap of enGene? | enGene's current market cap is $669M. |
| Is enGene profitable? | No, enGene is not profitable. |
| What is the current EBITDA of enGene? | enGene has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of enGene? | Current EBITDA multiple of enGene is (4.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.